Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for global healthcare providers. The company adheres to stringent manufacturing standards and offers flexible logistics to meet diverse market requirements.

Mirtazapine is indicated for depressive disorders, primarily acting on the central nervous system to alleviate depressive symptoms.

- Major depressive disorder: reduces depressive symptoms and improves overall functioning - Depressive symptoms with anxiety: may alleviate both mood and anxiety components - Treatment‑resistant depression (adjunctive): can be considered when other agents have not achieved adequate response

Mirtazapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Hepatic injury - Suicidal thoughts or behavior, especially early in treatment - Severe hypotension or syncope - Allergic reactions such as rash or angioedema

Before initiating therapy, clinicians should evaluate several safety considerations.

- Assess hepatic function: obtain baseline liver enzymes - Monitor weight: track changes due to increased appetite - Screen for suicidal ideation: especially during the first weeks - Avoid abrupt discontinuation: taper under medical supervision - Caution in elderly patients: higher risk of sedation and falls - Store at ambient temperature: keep in original container, protect from moisture

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome - Other serotonergic antidepressants (e.g., SSRIs, SNRIs): heightened serotonin toxicity - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression

Moderate Interactions (Monitor Closely): - Alcohol: may increase drowsiness and impair coordination - CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole): may raise mirtazapine plasma levels - Antihistamines: potential for enhanced sedation - Warfarin: monitor INR for possible anticoagulant effect alteration